A Catalytically Inactive Protein Kinase C alpha Mutation Drives Chordoid Glioma by Pathway Rewiring
Charlotte BellamyiD, Hannah TovelliD, Tiffany H. KaoiD, Alexandr P. KorneviD, Quentin LetourneuriD, Janan ArslaniD, Selina SchwaighoferiD, Timothy R. BaffiiD, Florent DingliiD, Damarys LoewiD, Julie LerondiD, Stéphane LivaiD, Brigitte IzaciD, Muriel AndrieuiD, Homa Adle‐BiassetteiD, Jean‐Vianney BarnieriD, Eduard StefaniD, Susan Serota TayloriD, Marc SansoniD, Alexandra C. NewtoniD, Franck BielleiD
Abstract
Abstract SummaryChordoid glioma (ChG) is a rare, low-grade brain tumor characterized by a novel recurrent point mutation, D463H, in the kinase domain of protein kinase C alpha (PKC). The mutation is invariably an Asp to His substitution, suggesting it endows a unique function beyond catalytic inactivation associated with other cancer-associated PKC mutations. Here we use in vitro and in cellulo activity assays to show that PKCD463H is catalytically inactive, functions as a dominant-negative mutant to suppress endogenous PKC and uniquely rewires the cellular interactome. Specifically, phosphoproteomic, proximity labeling, and co-immunoprecipitation mass-spectrometry data from cells overexpressing PKCD463H identify altered phosphorylation of substrates and binding to multiple proteins involved in cell-cell junctions compared to WT enzyme. Lastly, single nuclei RNAseq reveals that ChG derives from specialized tanycytes. Our data suggest that this disease-defining, fully penetrant mutation promotes neomorphic non-catalytic scaffolding to impair cell junction function.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 48th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The penetrant chordoid glioma PRKCA mutation is an oncogenic gain-of-function kinase inactivation eliciting early onset chondrosarcoma in mice.
Véronique Calleja, Jack C. Henry, … Peter J. Parker·Science SignalingPeer-reviewed·Nov 4, 2025
- Single-residue mutation in protein kinase C toggles between cancer and neurodegeneration
Alexander Curtis Jones, Alexandr P. Kornev, … Alexandra C. Newton·Biochemical JournalPeer-reviewed·Aug 8, 2023
- Golgi retention and oncogenic KIT signaling via PLCγ2-PKD2-PI4KIIIβ activation in GIST cells
Y. Obata, K. Kurokawa, … T. Nishida·bioRxiv·Dec 19, 2022
- Protein Kinase C gamma Mutations Drive Spinocerebellar Ataxia Type 14 by Impairing Autoinhibition
C. A. Pilo, T. R. Baffi, … A. C. Newton·bioRxiv·Jun 24, 2021
- Golgi retention of KIT in gastrointestinal stromal tumour cells is phospholipase D activity-dependent
Yuuki Obata, Miyuki Natsume, … Toshirou Nishida·Scientific ReportsPeer-reviewed·Aug 6, 2025
- A C-terminal motif containing a PKC phosphorylation site regulates γ-Protocadherin-mediated dendrite arborization in the cerebral cortex in vivo
Camille M. Hanes, Kar Men Mah, … Joshua A. Weiner·Developmental NeurobiologyPeer-reviewed·Jun 4, 2024